78 related articles for article (PubMed ID: 36120434)
1. Carnitine o-octanoyltransferase is a p53 target that promotes oxidative metabolism and cell survival following nutrient starvation.
Sanford JD; Franklin D; Grois GA; Jin A; Zhang Y
J Biol Chem; 2023 Jul; 299(7):104908. PubMed ID: 37307919
[TBL] [Abstract][Full Text] [Related]
2. Targeting PNPO to suppress tumor growth via inhibiting autophagic flux and to reverse paclitaxel resistance in ovarian cancer.
Li X; Guan W; Liu H; Yuan J; Wang F; Guan B; Chen J; Lu Q; Xu G; Zhang L
Apoptosis; 2024 Apr; ():. PubMed ID: 38615082
[TBL] [Abstract][Full Text] [Related]
3. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract][Full Text] [Related]
4. Emerging Roles for Ion Channels in Ovarian Cancer: Pathomechanisms and Pharmacological Treatment.
Altamura C; Greco MR; Carratù MR; Cardone RA; Desaphy JF
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562306
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Role of ITGBL1 in Ovarian Cancer.
Cortez AJ; Kujawa KA; Wilk AM; Sojka DR; Syrkis JP; Olbryt M; Lisowska KM
Cancers (Basel); 2020 Sep; 12(9):. PubMed ID: 32961775
[TBL] [Abstract][Full Text] [Related]
6. Drug resistance in ovarian cancer: from mechanism to clinical trial.
Wang L; Wang X; Zhu X; Zhong L; Jiang Q; Wang Y; Tang Q; Li Q; Zhang C; Wang H; Zou D
Mol Cancer; 2024 Mar; 23(1):66. PubMed ID: 38539161
[TBL] [Abstract][Full Text] [Related]
7. SMAD4 inhibits glycolysis in ovarian cancer through PI3K/AKT/HK2 signaling pathway by activating ARHGAP10.
Wu K; Gong W; Sun H; Li W; Chen L; Duan Y; Zhu J; Zhang H; Ke H
Cancer Rep (Hoboken); 2024 Jan; 7(2):e1976. PubMed ID: 38230565
[TBL] [Abstract][Full Text] [Related]
8. Cyclin dependent kinase 14 as a paclitaxel-resistant marker regulated by the TGF-β signaling pathway in human ovarian cancer.
Guan W; Yuan J; Li X; Gao X; Wang F; Liu H; Shi J; Xu G
J Cancer; 2023; 14(13):2538-2551. PubMed ID: 37670966
[TBL] [Abstract][Full Text] [Related]
9. "DEPHENCE" system-a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer-a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies.
Wilczyński JR; Wilczyński M; Paradowska E
Front Oncol; 2023; 13():1201497. PubMed ID: 37448521
[TBL] [Abstract][Full Text] [Related]
10. MCF2L-AS1 promotes the biological behaviors of hepatocellular carcinoma cells by regulating the miR-33a-5p/FGF2 axis.
Ou H; Qian Y; Ma L
Aging (Albany NY); 2023 Jul; 15(13):6100-6116. PubMed ID: 37432067
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.
Saburi A; Kahrizi MS; Naghsh N; Etemadi H; İlhan A; Adili A; Ghoreishizadeh S; Tamjidifar R; Akbari M; Ercan G
J Ovarian Res; 2022 Jul; 15(1):81. PubMed ID: 35799305
[TBL] [Abstract][Full Text] [Related]
13. The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance - A focus on signaling pathways interplay.
Ismail A; Abulsoud AI; Fathi D; Elshafei A; El-Mahdy HA; Elsakka EGE; Aglan A; Elkhawaga SY; Doghish AS
Pathol Res Pract; 2022 Dec; 240():154222. PubMed ID: 36413828
[TBL] [Abstract][Full Text] [Related]
14. The miR-33a-5p/CROT axis mediates ovarian cancer cell behaviors and chemoresistance
Li X; Gao X; Yuan J; Wang F; Xu X; Wang C; Liu H; Guan W; Zhang J; Xu G
Front Endocrinol (Lausanne); 2022; 13():950345. PubMed ID: 36120434
[TBL] [Abstract][Full Text] [Related]
15. A novel homeostatic loop of sorcin drives paclitaxel-resistance and malignant progression via Smad4/ZEB1/miR-142-5p in human ovarian cancer.
Zhang J; Guan W; Xu X; Wang F; Li X; Xu G
Oncogene; 2021 Jul; 40(30):4906-4918. PubMed ID: 34163033
[TBL] [Abstract][Full Text] [Related]
16. CircATL2 enhances paclitaxel resistance of ovarian cancer via impacting miR-506-3p/NFIB axis.
Ying H; Zhao R; Yu Q; Zhang K; Deng Q
Drug Dev Res; 2022 Apr; 83(2):512-524. PubMed ID: 34541682
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
